Navigation Links
Amgen Establishes Commercial Operations in Brazil
Date:4/8/2011

THOUSAND OAKS, Calif., April 8, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN), the world's largest biotechnology company, announced today the expansion of its operations in Brazil, including the acquisition of Bergamo, a privately-held Brazilian pharmaceutical company. Amgen has also agreed to reacquire rights in Brazil to its products that were previously granted to Mantecorp (subsequently acquired by Hypermarcas). Together, these transactions will provide Amgen a significant presence in Brazil and immediate, direct access to one of the fastest growing pharmaceutical markets in the world.

Bergamo is a leading supplier of medicines to the hospital sector in Brazil with capabilities in oncology medicines and has manufacturing facilities in Sao Paulo state. Bergamo had gross revenues of US $80 million in 2010 and has been growing at an annual rate of 19 percent since 2007. Under terms of the transaction announced today, Amgen gained full ownership of Bergamo by purchasing it for approximately US $215 million.

Amgen has entered into an agreement in principle with Hypermarcas to reacquire the rights in Brazil to several of Amgen's innovative medicines, two of which are already approved in Brazil, Vectibix® (panitumumab) and Mimpara® (cinacalcet), and a third, romiplostim, (registered as Nplate® in the United States), a treatment for the blood disorder ITP, which is currently under review by ANVISA, the regulatory authority in Brazil.

"Amgen's strategic goal is to make our innovative medicines available to patients in major markets around the world," said Kevin Sharer, Amgen's chairman and chief executive officer.  "Acquiring Bergamo, a profitable company with an established local infrastructure, and regaining the rights to our products in Brazil, provides us an attractive entry into the Brazilian market."

The focus on Brazil is part of
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015 /PRNewswire/ ... a three-dimensional biology company focused on delivering scientific ... announced that the Company has hired Paul ... in vitro tissue service and product business. Mr. Gallant ... R&D experience in the drug discovery industry, most ...
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015  Mirati Therapeutics, ... focusing on genetic and epigenetic drivers of cancer, will be ... August 11, 2015 at 1:55 p.m. ET (10:55 a.m. PT) ... Baum , M.D., Ph.D., president and CEO of Mirati, will ... of the presentation will be accessible on the "Investors" page ...
(Date:8/3/2015)... 2015   The Intellectual Property and Science ... provider of intelligent information for businesses and professionals ... Pharmaceutical R&D Factbook , the biopharmaceutical industry,s leading ... declines in R&D, the analysis identifies a surge ... and forecasts sales to reach $1.3 trillion by ...
Breaking Medicine Technology:Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3Pharma Sales to Grow Beyond $1 Trillion 2
... June 21, 2010 ReportsandReports announces it Will,Carry Cardiovascular Devices Market ... , , ... http://www.reportsandreports.com/market-reports/netherlands-cardiovascular-de ,vices-market-outlook-to-2016/) , , , ... (Due to the length of these URLs, it may be necessary to copy ...
... AHMEDABAD, India , June 21, 2010 ... healthcare companies has,received Phase I clinical trial permission from the DCGI for ... Centre using a,unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule. ... ...
Cached Medicine Technology:Cardiovascular Devices Market Outlook June Update by ReportsandReports 2Cardiovascular Devices Market Outlook June Update by ReportsandReports 3Cardiovascular Devices Market Outlook June Update by ReportsandReports 4Cardiovascular Devices Market Outlook June Update by ReportsandReports 5Cardiovascular Devices Market Outlook June Update by ReportsandReports 6Cardiovascular Devices Market Outlook June Update by ReportsandReports 7Cardiovascular Devices Market Outlook June Update by ReportsandReports 8Cardiovascular Devices Market Outlook June Update by ReportsandReports 9Cardiovascular Devices Market Outlook June Update by ReportsandReports 10Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial 2Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial 3
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... the launch of a new product suite designed to provide pharmaceutical and healthcare ... trends based on multi-sourced and cross-referenced data from regulatory filings (including the FDA ...
(Date:8/4/2015)... ... August 04, 2015 , ... Armadale Capital ... announced the closing of a $118 million FHA-insured loan modification refinancing for Johnston ... Smithfield and Clayton, North Carolina. JHSC is a joint venture of Johnston ...
(Date:8/4/2015)... ... August 04, 2015 , ... Updated enrollment data on the top U.S. health ... be accessed at http://www.AISHealth.com . The data is free to all registered users ... tables and charts on the website’s “Data” section include:, , ...
(Date:8/4/2015)... ... August 04, 2015 , ... Oriental ... and crafts, toys, novelties, and school supplies, has developed engaging and affordable teacher ... exclusive collection includes student rewards, classroom decorations, crafts and educational resources featuring ...
(Date:8/4/2015)... ... 2015 , ... Mercy Health (formerly Catholic Health Partners) – a Catholic healthcare ministry serving Ohio ... Well videos to preparing high school athletes for fall sports. , In a concise video ... , What steps to take to help prevent injuries , ...
Breaking Medicine News(10 mins):Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 2Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 3Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3Health News:Mercy Health Video Provides Helpful Information for High School Athletes 2
... HealthDay Reporter , TUESDAY, Sept. 6 (HealthDay News) ... as ibuprofen during the first stage of their pregnancy ... suggests. "We,re seeing a 2.4-fold increased risk ... pregnancy," said Anick Berard, senior author of a paper ...
... U.S. Food and Drug Administration (FDA) clears the path for ... estimating the risk of ovarian cancer in women with a ... and use of a combination of blood tests for proteins ... (ROMA). Research demonstrates that examining levels of HE4 and CA125 ...
... PARK, Md. - Amid ongoing concerns about E. coli, ... take a unique approach to make imports bound for ... those foods intensive, hands-on lab training in U.S. government ... "The more we can get foreign food facilities ...
... German . The stomach bacterium Helicobacter pylori ... gastric cancer, the third most common cause of cancer-related deaths in ... identified a mechanism of Helicobacter pylori that damages the DNA of ... transformation. Gastric cancer is one of the most common and ...
... cells is an effective treatment for patients with malignant ... cells are crucial to the outcome. Researchers from Lund ... the quality of the transplanted cells using ultrasound for ... blood stem cell transplant is often the only treatment ...
... , This release is available in German . ... they react with a suitable behavioural response and do not ... is the case, for example, with patients who suffer from ... from the Max Planck Institute of Psychiatry have discovered two ...
Cached Medicine News:Health News:NSAIDs May Raise Miscarriage Risk: Study 2Health News:NSAIDs May Raise Miscarriage Risk: Study 3Health News:FDA clears biomarker test for ovarian cancer 2Health News:FDA clears biomarker test for ovarian cancer 3Health News:For safer food imports, Teach foreign lab workers US requirements 2Health News:For safer food imports, Teach foreign lab workers US requirements 3Health News:Stomach bacterium damages human DNA 2Health News:Ultrasound improves stem cell transplants 2Health News:Control of fear in the brain decoded 2Health News:Control of fear in the brain decoded 3
... Cost-effective, portable, continuous, or spot ... with alarms and an internal ... and Sleep Study modes make ... the hospital or clinical environment; ...
... The Autocorr Plus, the fourth ... cost-effective, versatile pulse oximeter/ECG/Respiration Monitor, with ... detect/reject, digital oximetry with SAC (Serial ... high-resolution electroluminescent screen display provides two ...
... Management Program is a Windows based, easy-to-use ... Hand-Held Pulse Oximeter. Using the Smiths ... it rapidly downloads information collected during sleep ... and assists in the Clinician's interpretation by ...
The automated and pivoting M2 hand-piece incorporates two powerful, independent electric motors : one controls the blade oscillation at 15,000 RPM and the second controls the high-torque advance of t...
Medicine Products: